|
Post by dreamboatcruise on Mar 28, 2017 9:54:35 GMT -5
And the 30 4 unit + 60 8 unit = 360 units is $321 with the GoodRx coupon. We know it requires more Afrezza for most patients, but it seems Afrezza pricing isn't significantly higher as some continue to suggest here. Does anyone know if the GoodRx coupon can be combined with the Mannkind $150 discount coupon?
|
|
|
Post by peppy on Mar 28, 2017 9:55:24 GMT -5
heh holdem, the cure the risk. Thank you. so thinking it through further, the risk is if the cell in not getting glucose, at all the cells will die. soooo, you are saying that cell death is a long process, should be more immediate.....
in the hyperglycemia/ glucose in the blood, not getting in the cell scenario. hmmmm
Cells in general do not die of hyperglycemia. The exception is the beta cells but that's a different aspect and takes a while. Also if cells are not getting the energy they need from glucose the body switches to ketosis and they get the energy from ketones instead. The exception to this is the brain which can only use glucose but obviously with hyperglycemia that is not a problem. thank you aged, so why aren't these examples (taken at their word) dying of ketosis in short order? www.diabetes.org/living-with-diabetes/complications/ketoacidosis-dka.html just asking
|
|
|
Post by dreamboatcruise on Mar 28, 2017 9:56:01 GMT -5
I think Afrezza the Drug will survive. However it will survive in some other company's hands. MNKD the Company, MNKD the Investment is dead, Dead... DEAD. Bankruptcy is looming near on the horizon. IF (and that's a very big If) MNKD can survive, the resulting dilution will be huge.. likely another 50%. At this moment MNKD stock is worth 35 cents in pre-split terms. It will be the 15 cent stock that Goldman and Jason Karp predicted before too much longer. Think about it.No thanks... West Coast it is still too early to start drinking.
|
|
|
Post by saxcmann on Mar 28, 2017 10:00:04 GMT -5
Sports: I feel your frustration. I hope you will post more I look for your post because they are informed and interesting. My money is gone, or it is on paper. At this point I'm not even thinking about it. I have to focus on making money in other stocks. I had a investor tell me he was scared to death to buy another stock. Really? Just pick one. They're almost all going up! My frustration comes from knowing how worried the people that are on Afrezza are. They can't imagine life with out it! The company as we all know has to do something to stabilize it's self. People are under so much stress. Al Mann once again built the better mousetrap...But almost nobody knows! I feel ya sports. Lost hundreds of thousands on paper. So sad knowone knows about afrezza and it cost so much. Hope PWD who discovered afrezza can stay on it.
|
|
|
Post by silentknight on Mar 28, 2017 10:00:58 GMT -5
I think Afrezza the Drug will survive. However it will survive in some other company's hands. MNKD the Company, MNKD the Investment is dead, Dead... DEAD. Bankruptcy is looming near on the horizon. IF (and that's a very big If) MNKD can survive, the resulting dilution will be huge.. likely another 50%. At this moment MNKD stock is worth 35 cents in pre-split terms. It will be the 15 cent stock that Goldman and Jason Karp predicted before too much longer. Think about it. I'm quite interested in what exactly has changed in the two weeks since q4 earnings were announced to bring on this extremely negative sentiment. Were you expecting much better scripts? The PPS decline? Did something else happen? There hasn't been any changes and the market sees that as inherently negative. MNKD expected increases in scripts. There hasn't been, and all the while, they're burning $10 million per month on a dwindling cash reserve. Even if the sales team can deliver massive script sales in short order (they won't) the company will run out of money before it's profitable. I'm suspect that any decent financing will come along, so that leaves the company with two viable options...1) dilute existing shareholders in a massive way to generate more money, or 2) file Chapter-11/Chapter-7. It's folly to believe that a partnership or buyout is coming, so there are no other viable sources of income. They can't sell their drug, as they've demonstrated, so the remaining options destroy shareholders either way. I'd get out now, but honestly the pennies I'd get out of it is insignificant to me. I've already lost it all. Might as well wait and pray for a hail mary.
|
|
|
Post by saxcmann on Mar 28, 2017 10:05:20 GMT -5
I'm quite interested in what exactly has changed in the two weeks since q4 earnings were announced to bring on this extremely negative sentiment. Were you expecting much better scripts? The PPS decline? Did something else happen? There hasn't been any changes and the market sees that as inherently negative. MNKD expected increases in scripts. There hasn't been, and all the while, they're burning $10 million per month on a dwindling cash reserve. Even if the sales team can deliver massive script sales in short order (they won't) the company will run out of money before it's profitable. I'm suspect that any decent financing will come along, so that leaves the company with two viable options...1) dilute existing shareholders in a massive way to generate more money, or 2) file Chapter-11/Chapter-7. It's folly to believe that a partnership or buyout is coming, so there are no other viable sources of income. They can't sell their drug, as they've demonstrated, so the remaining options destroy shareholders either way. I'd get out now, but honestly the pennies I'd get out of it is insignificant to me. I've already lost it all. Might as well wait and pray for a hail mary. Exactly!!!
|
|
|
Post by alethea on Mar 28, 2017 10:07:17 GMT -5
I think Afrezza the Drug will survive. However it will survive in some other company's hands. MNKD the Company, MNKD the Investment is dead, Dead... DEAD. Bankruptcy is looming near on the horizon. IF (and that's a very big If) MNKD can survive, the resulting dilution will be huge.. likely another 50%. At this moment MNKD stock is worth 35 cents in pre-split terms. It will be the 15 cent stock that Goldman and Jason Karp predicted before too much longer. Think about it. I'm quite interested in what exactly has changed in the two weeks since q4 earnings were announced to bring on this extremely negative sentiment. Were you expecting much better scripts? The PPS decline? Did something else happen? I lost faith during the recent call when the Reverse Split was announced. Sold 75% the next morning at $.64 ($3.20 post split). I sold the rest a few minutes before the recent conf call at about $.41 (2.05 post split). I lauded and praised Matt last Nov 9 or so when he improved the financial position of MNKD by almost $130 million with the Sanofi settlement. A great job. Well done. THAT was 5 months ago. They continue to spend cash at $10 million per month while selling less than 300 scrips per week. THEY WILL SOON BE OUT OF CASH. Apparently with zero prospects of raising any funds. Certainly none they are willing to share with investors with 95% losses. I guess we're "on or own" I am/was an accountant/CPA. It doesn't take Warren Buffet to see that the financial prospects of MNKD are hopeless. I always thought the Mann Foundation or a Bill Gates-like investor would bolster them long enough to get Sales going. I no longer believe that. THREE fricking years now since FDA approval and 250 scrips per week. I am ashamed that I stuck with this investment as long as I did.
|
|
|
Post by agedhippie on Mar 28, 2017 10:22:37 GMT -5
Cells in general do not die of hyperglycemia. The exception is the beta cells but that's a different aspect and takes a while. Also if cells are not getting the energy they need from glucose the body switches to ketosis and they get the energy from ketones instead. The exception to this is the brain which can only use glucose but obviously with hyperglycemia that is not a problem. thank you aged, so why aren't these examples (taken at their word) dying of ketosis in short order? www.diabetes.org/living-with-diabetes/complications/ketoacidosis-dka.html just asking
Because you get to ER PDQ and then there is only a 1% chance of dying. The trick is to get to hospital before the vomiting starts, then it's very survivable. If you are in DKA and do not make hospital then you are almost certainly dead in hours - seen it happen twice. What happens in DKA? Well first you start feeling ill and test - you are somewhere over 300 and worse, you forgot to bring your insulin. Get on a train going home because you are not thinking clearly, by now you are beginning to feel seriously ill. Then the vomiting starts. You are getting dehydrated. You are not going anywhere. You can't seem to quite catch your breath. You are peeing like a racehorse and still vomiting. It's probably about two hours after this started. Ok - that's it. If you are not in hospital immediately the next bit is percussive breathing (heavy panting as your body attempts to dump ketone by-products via your breath because vomiting and peeing isn't coping - mildly ironic since you feel you can't breathe), coma, and death. Even if you make hospital at this point you are going straight into the ICU.
|
|
|
Post by peppy on Mar 28, 2017 10:24:04 GMT -5
And the 30 4 unit + 60 8 unit = 360 units is $321 with the GoodRx coupon. We know it requires more Afrezza for most patients, but it seems Afrezza pricing isn't significantly higher as some continue to suggest here. Does anyone know if the GoodRx coupon can be combined with the Mannkind $150 discount coupon? quote: I am ashamed that I stuck with this investment as long as I did.
I am ashamed too. I am ashamed, I wasn't cut throat enough to take my gains. I am ashamed I would not take a loss. I am shamed the loss is so huge. I am ashamed at the greed I felt. I am shamed I thought once medicine saw how well this insulin controlled blood sugar, it would be prescribed as labeled to type one. I am ashamed I did not know about pharmacy purchasing manufactures, labels and the food and drug administration. I only saw, smiling happy people.
|
|
|
Post by slapshot on Mar 28, 2017 10:24:15 GMT -5
And the 30 4 unit + 60 8 unit = 360 units is $321 with the GoodRx coupon. We know it requires more Afrezza for most patients, but it seems Afrezza pricing isn't significantly higher as some continue to suggest here. Does anyone know if the GoodRx coupon can be combined with the Mannkind $150 discount coupon? What exactly are you comparing when you say "it seems Afrezza pricing isn't significantly higher as some continue to suggest here"? $510 for 5 - 3ml pens @ 100 units /ml Humalog = $510 for 1500 units = $0.34 / unit for Humalog. $614 for 1040 units Afrezza = $0.59 / unit for Afrezza... $321 for 350 units Afrezza = $0.92 / unit... This does not even factor in that Afrezza is also limited by its cartridge's... likely requires at least 6 cartridges a day. Anyway, if the 1040 units Afrezza lasts a month, it would require 3x for a 3 month period which would be $1842 for 3 months, while 1500 units Humalog would correspondingly last a month and a half so require purchasing only 2x for a 3 month period so would be $1020 for 3 months... Which would you rather pay 1000 or 1800 every 3 months?
|
|
|
Post by madog365 on Mar 28, 2017 10:26:03 GMT -5
I'm quite interested in what exactly has changed in the two weeks since q4 earnings were announced to bring on this extremely negative sentiment. Were you expecting much better scripts? The PPS decline? Did something else happen? There hasn't been any changes and the market sees that as inherently negative. MNKD expected increases in scripts. There hasn't been, and all the while, they're burning $10 million per month on a dwindling cash reserve. Even if the sales team can deliver massive script sales in short order (they won't) the company will run out of money before it's profitable. I'm suspect that any decent financing will come along, so that leaves the company with two viable options...1) dilute existing shareholders in a massive way to generate more money, or 2) file Chapter-11/Chapter-7. It's folly to believe that a partnership or buyout is coming, so there are no other viable sources of income. They can't sell their drug, as they've demonstrated, so the remaining options destroy shareholders either way. I'd get out now, but honestly the pennies I'd get out of it is insignificant to me. I've already lost it all. Might as well wait and pray for a hail mary. I think there is a decent amount of developments going on on the sales and marketing front. They are hustling - with not much success to show, yet. To me, a more fair criticism would be to ask what is Matt getting done as the CEO? His primary job function is to bring value to shareholders and thus far i'm not seeing any of that value.
|
|
|
Post by Cowgirl on Mar 28, 2017 10:31:51 GMT -5
"I always thought the Mann Foundation or a Bill Gates-like investor would bolster them long enough to get Sales going."
Mann Foundation money gone with the plunge in price of MNKD stock. With no ability to gain a controlling stake investors are staying away...
|
|
|
Post by peppy on Mar 28, 2017 10:32:23 GMT -5
And the 30 4 unit + 60 8 unit = 360 units is $321 with the GoodRx coupon. We know it requires more Afrezza for most patients, but it seems Afrezza pricing isn't significantly higher as some continue to suggest here. Does anyone know if the GoodRx coupon can be combined with the Mannkind $150 discount coupon? What exactly are you comparing when you say "it seems Afrezza pricing isn't significantly higher as some continue to suggest here"? $510 for 5 - 3ml pens @ 100 units /ml Humalog = $510 for 1500 units = $0.34 / unit for Humalog. $614 for 1040 units Afrezza = $0.59 / unit for Afrezza... $321 for 350 units Afrezza = $0.92 / unit... This does not even factor in that Afrezza is also limited by its cartridge's... likely requires at least 6 cartridges a day. Anyway, if the 1040 units Afrezza lasts a month, it would require 3x for a 3 month period which would be $1842 for 3 months, while 1500 units Humalog would correspondingly last a month and a half so require purchasing only 2x for a 3 month period so would be $1020 for 3 months... Which would you rather pay 1000 or 1800 every 3 months? I was attempting to look at costs per month? trying to. insurer costs and then the distribution I guess. you broke it down into unit cost. Breaking cost down, the cost to insurer is higher per month? by 1/3? That is the nut?
|
|
|
Post by silentknight on Mar 28, 2017 10:48:24 GMT -5
There hasn't been any changes and the market sees that as inherently negative. MNKD expected increases in scripts. There hasn't been, and all the while, they're burning $10 million per month on a dwindling cash reserve. Even if the sales team can deliver massive script sales in short order (they won't) the company will run out of money before it's profitable. I'm suspect that any decent financing will come along, so that leaves the company with two viable options...1) dilute existing shareholders in a massive way to generate more money, or 2) file Chapter-11/Chapter-7. It's folly to believe that a partnership or buyout is coming, so there are no other viable sources of income. They can't sell their drug, as they've demonstrated, so the remaining options destroy shareholders either way. I'd get out now, but honestly the pennies I'd get out of it is insignificant to me. I've already lost it all. Might as well wait and pray for a hail mary. I think there is a decent amount of developments going on on the sales and marketing front. They are hustling - with not much success to show, yet. To me, a more fair criticism would be to ask what is Matt getting done as the CEO? His primary job function is to bring value to shareholders and thus far i'm not seeing any of that value. They've been hustling for a while with no success. That's the problem. I blame Matt for continually saying stupid things, but I hold the Board responsible for failing shareholders. Ultimately, they're the ones calling the shots. I said it before but I'll vote every share I have to remove them all if MNKD makes it to have another shareholder meeting.
|
|
|
Post by sportsrancho on Mar 28, 2017 11:11:29 GMT -5
I think there is a decent amount of developments going on on the sales and marketing front. They are hustling - with not much success to show, yet.
To me, a more fair criticism would be to ask what is Matt getting done as the CEO? His primary job function is to bring value to shareholders and thus far i'm not seeing any of that.
I hold the Board responsible for failing shareholders. Ultimately, they're the ones calling the shots. I said it before but I'll vote every share I have to remove them all if MNKD makes it to have another shareholder meeting.
Agree with the above.
|
|